Increased anterior chamber penetration of topical levofloxacin 0.5% after pulsed dosing in cataract patients

Acta Ophthalmologica

Volumn 87, Issue 2, 2009, Pages 160-165

  Sundelin, Karin ^a   Seal, David ^b   Gardner, Susanne ^c   Ropo, Auli ^d   Geldsetzer, Klaus ^e   Lokkila, Jukka ^d   Stenevi, Ulf ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b CITY UNIVERSITY   (United Kingdom)

^c OTM Inc   (United States)

^d Santen Oy   (Finland)

^e SANTEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Aqueous humour levels; Cataract surgery; Levofloxacin; Pharmacokinetics; Prophylaxis

Indexed keywords

LEVOFLOXACIN; OFTAQUIX; UNCLASSIFIED DRUG;

ADULT; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CATARACT; CATARACT EXTRACTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PHACOEMULSIFICATION; PRIORITY JOURNAL;

ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; ANTERIOR CHAMBER; ANTI-BACTERIAL AGENTS; CATARACT EXTRACTION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; OSMOLAR CONCENTRATION; PHACOEMULSIFICATION; POSTOPERATIVE CARE; PREOPERATIVE CARE; PULSE THERAPY, DRUG; TIME FACTORS;

EID: 61549094663     PISSN: 1755375X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2008.01358.x     Document Type: Article

References (24)

1. Aminimanizani A, Beringer P Jelliffe R (2001 Comparative pharmacokinetic and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet 40 : 169 187.
2. Barry P, Behrens-Baumann W, Pleyer U Seal D (eds 2007 ESCRS Guidelines on Prevention, Investigation and Management of Postoperative Endophthalmitis, Version 2. Dublin : European Society of Cataract & Refractive Surgeons 8 14.
3. Bucci FA (2004 An in vivo study comparing the ocular absorption of levofloxacin and ciprofloxacin prior to phacoemulsification. Am J Ophthalmol 137 : 308 312.
4. Colin J, Simonpoli S, Geldsetzer K Ropo A (2003 Corneal penetration of levofloxacin into the human aqueous humour: a comparison with ciprofloxacin. Acta Ophthalmol Scand 81 : 611 613.
5. Drago F De Bernardis E (1994 Lachrymal concentration of norfloxacin after a single ocular instillation in humans. Eur J Ophthalmol 4 : 102 104.
6. Drlica K Zhao X (1997 DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 61 : 377 392.
7. European Society of Cataract & Refractive Surgeons Endophthalmitis Study Group (2007 Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicentre study and identification of risk factors. J Cataract Refract Surg 33 : 978 988.
8. Gardner SK (1987 Ocular drug penetration and pharmacokinetic principles. In : Lamberts DW Potter DE (eds) Clinical Ophthalmic Pharmacology. Boston/Toronto : Little, Brown & Co. 1 52.
9. Glasser DB, Gardner S, Ellis JG Pettit TH (1985 Loading doses and extended dosing intervals in topical gentamicin therapy. Am J Ophthalmol 99 : 329 332.
10. Healy DP, Holland EJ, Nordlund ML, Dunn S, Chow C, Lindstrom RL, Hardten D Davis E (2004 Concentrations of levofloxacin, ofloxacin and ciprofloxacin in human corneal stromal tissue and AH after topical administration. Cornea 23 : 255 263.
11. Kim SY, Lim JA, Choi JS, Choi EC Joo CK (2007 Comparison of antibiotic effect ad corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro. Cornea 26 : 720 725.
12. Klepser ME, Ernst E, Petzold CR, Rhomberg P Doern GV (2001 Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model. Antimicrob Agents Chemother 45 : 673 678.
13. Koch HR, Kulus SC, Roessler M, Ropo A Geldsetzer K (2005 Corneal penetration of fluoroquinolones: aqueous humour concentrations after topical application of levofloxacin 0.5% and ofloxacin 0.3% eyedrops. J Cataract Refract Surg 31 : 1377 1385.
14. Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC Gordon YJ (2003 Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 136 : 500 505.
15. Kresken M Behrens-Baumann W (2007 Resistance to antibacterial agents amongst pathogens causing superficial ocular infections. [In German.] J Chemother 16 : 49 59.
16. Mather R, Karenchak LM, Romanowski MS Kowalski MS (2002 Fourth-generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 133 : 463 466.
17. Odenholt I Cars O (2006 Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. J Antimicrob Chemother 58 : 960 965.
18. Sakamoto H, Sakamoto M, Hata Y, Kubota T Ishibashi T (2007 Aqueous and vitreous penetration of levofloxacin after topical and/or oral administration. Eur J Ophthalmol 17 : 372 376.
19. Sasaki K, Mitsui Y, Fukuda M, Ooishi M Ohashi Y (1995 Intraocular penetration mode of five fluoroquinolone ophthalmic solutions evaluated by the newly proposed parameter of AQC max. J Eye 12 : 787 789.
20. Seal DV Pleyer U (2007). Pharmacology and pharmacokinetics. In : Ocular Infection, 2nd edn. New York : Informa Healthcare 105 125.
21. Smith HJ, Walters M, Hisanaga T, Zhanek GG Hoban DJ (2004 Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob Agents Chemother 48 : 3954 3958.
22. Stroman DW, Cupp G, Dahlin DC, Schlech BA D'Arienzo PA (2006 Human ocular concentrations following topical fluoroquinolone administration relative to susceptibility of ocular pathogens. Invest Ophthalmol Vis Sci 47 : E-Abstract 1881-B242.
23. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM) (2001 Guidance for Industry, Bioanalytical method validation [ http://www.fda.gov/CDER/GUIDANCE/4252fnl.htm ].
24. 0-t/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. J Antimicrob Chemother 51 : 905 911.